Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.53 |
| ▸ | MDM4 | O15151 | 3/20 | 0.52 |
| ▸ | TP53 | P04637 | 3/20 | 0.52 |
| ▸ | CASP1 | P29466 | 3/20 | 0.47 |
| ▸ | TNF | P01375 | 1/20 | 0.46 |
| ▸ | MDM2 | Q00987 | 4/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30802532 | 1.00 | CASP3 (0.53) | CASP3MDM4TP53CASP1TNF | |
| SCHEMBL119369 | 1.00 | CASP3 (0.53) | CASP3MDM4TP53CASP1TNF | |
| SCHEMBL30826385 | 1.00 | CASP3 (0.53) | CASP3MDM4TP53CASP1TNF | |
| SCHEMBL8037759 | 1.00 | CASP3 (0.53) | CASP3MDM4TP53CASP1TNF | |
| SCHEMBL30641530 | 1.00 | CASP3 (0.53) | CASP3MDM4TP53CASP1TNF | |
| SCHEMBL10187049 | 1.00 | CASP3 (0.53) | CASP3MDM4TP53CASP1TNF | |
| SCHEMBL29400275 | 1.00 | CASP3 (0.53) | CASP3MDM4TP53CASP1TNF | |
| SCHEMBL29864868 | 0.96 | CASP1 (0.50) | CASP3MDM4TP53CASP1TNF | |
| SCHEMBL31166669 | 0.96 | CASP1 (0.50) | CASP3MDM4TP53CASP1TNF | |
| SCHEMBL15101019 | 0.93 | CASP3 (0.49) | CASP3MDM4TP53CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 223 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119161446-B | Process for preparing amylin analogues | 杭州诺泰诺和生物医药科技有限公司 | 2025-02-14 | — | — | CN | claimed |
| CN-119161446-A | Process for preparing amylin analogues | 杭州诺泰诺和生物医药科技有限公司 | 2024-12-20 | — | — | CN | claimed |
| CN-118324868-A | Process for the preparation of desmopressin EP impurities E and F | 梯尔希（南京）药物研发有限公司 | 2024-07-12 | — | — | CN | claimed |
| CN-113621022-B | Synthesis method of cyclic peptide | 甘肃瑞德林生物有限公司 | 2024-05-28 | — | — | CN | claimed |
| CN-117088966-A | Synthesis method of bivalirudin impurity | 江苏诺泰澳赛诺生物制药股份有限公司 | 2023-11-21 | — | — | CN | claimed |
| CN-112062829-B | Preparation method of elcatonin | 杭州固拓生物科技有限公司 | 2023-02-28 | — | — | CN | claimed |
| CN-114349827-A | Synthetic method of brennuo peptide | 江苏诺泰澳赛诺生物制药股份有限公司 | 2022-04-15 | — | — | CN | claimed |
| EP-4731637-A1 | METHODS OF CHEMICAL SYNTHESIS OF PEPTIDES | Imperial College Innovations Limited (GB) | 2026-04-29 | — | — | EP | disclosed |
| EP-4729094-A2 | Modulators of complement activity | UCB Holdings, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4727655-A1 | DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | Mariana Oncology Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4727654-A1 | DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | Mariana Oncology Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4729529-A1 | PREPARATION OF PEPTIDE INHIBITOR OF INTERLEUKIN-23 RECEPTOR AND USE THEREOF | Xizang Haisco Pharmaceutical Co., Ltd. (CN) | 2026-04-22 | — | — | EP | disclosed |
| EP-4727653-A1 | DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | Mariana Oncology Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-3973994-A1 | MODULATION OF COMPLEMENT ACTIVITY | RA Pharmaceuticals, Inc. (US) | 2022-03-30 | — | — | EP | disclosed |
| US-11286280-B2 | Melanocortin-1 receptor-specific peptides for cytokine storm and inflammation therapy | PALATIN TECHNOLOGIES, INC. (US) | 2022-03-29 | — | — | US | disclosed |
| US-20220088146-A1 | Melanocortin Receptor-Specific Peptide Formulations and Methods for Gastrointestinal Tract-Specific Delivery | PALATIN TECHNOLOGIES INC (US) | 2022-03-24 | — | — | US | disclosed |
| WO-2022050529-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | ㈜베르티스 | 2022-03-10 | — | — | WO | disclosed |
| CN-107667120-B | anti-MUC 16 antibodies and uses thereof | 纪念斯隆-凯特林癌症中心 | 2022-03-08 | — | — | CN | disclosed |
| EP-3958842-A1 | COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT ACTIVITY | RA Pharmaceuticals, Inc. (US) | 2022-03-02 | — | — | EP | disclosed |
| WO-2022038417-A2 | MODIFIED IL-18 POLYPEPTIDES AND USES THEREOF | BRIGHT PEAK THERAPEUTICS AG (CH) | 2022-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11286280-B2 | Melanocortin-1 receptor-specific peptides for cytokine storm and inflammation therapy | MC3R, MC1R, MC2R | CASP3 2754/4885MDM4 4380/4885TP53 3497/4885 |
| US-20220088146-A1 | Melanocortin Receptor-Specific Peptide Formulations and Methods for Gastrointestinal Tract-Specific Delivery | MC3R, GIPR, MC1R | CASP3 4595/4885MDM4 4773/4885TP53 3820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.